4th Quarter - Report

HOWARD CONSULTING GROUP, INC. for PHRMA ON BEHALF OF WE WORK FOR HEALTH

Firm
Client
Income
$20,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

-The impact of medical innovation on the local economy -The impact of Biosimilars legislation on the pharmaceutical industry -Prevention and wellness education programs focused on chronic disease -Senate Finance Committee options papers -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics -The "America's Healthy Futures Act of 2009"

LobbyistCovered position, as disclosed
FRANK HOWARD —
JOHN MARCHANT —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1427 (111th), S. 726 (111th), H.R. 1548 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.